Gamma Delta T Cell Cancer Therapy Market Report 2025

The gamma delta T cell cancer therapy market size has grown rapidly in recent years. It will grow from $1.77 billion in 2024 to $2.11 billion in 2025 at a compound annual growth rate (CAGR) of 18.9%. The growth in the historic period can be attributed to the rising incidence of cancer, increasing awareness of cell-based therapies, expansion of immuno-oncology research, growing clinical trial activity in immunotherapy, and a heightened demand for safer and more effective immunotherapies.

The gamma delta T cell cancer therapy market size is expected to see rapid growth in the next few years. It will grow to $4.17 billion in 2029 at a compound annual growth rate (CAGR) of 18.6%. The growth in the forecast period can be attributed to the rising demand for personalized cancer treatments, an increased focus on reducing graft-versus-host disease, growing adoption of off-the-shelf cell therapy products, expansion of the gamma delta T cell therapy pipeline, and increasing use of gamma delta T cells in treating solid tumors. Key trends during this period include the development of combination immunotherapies, advances in cryopreservation techniques, integration of artificial intelligence in therapy design, use of multi-omics approaches for precise tumor targeting, and innovations in modulating the tumor microenvironment.

The growing number of clinical trials is expected to drive growth in the gamma delta (γδ) T cell cancer therapy market. Clinical trials are essential research studies conducted in humans to assess the safety, efficacy, and potential side effects of medical treatments. The increase in trials is fueled by rising demand for novel therapies to address unmet medical needs and improve patient outcomes. Clinical trials support γδ T cell cancer therapy development by validating safety and efficacy, accelerating regulatory approvals, and enabling optimized treatment protocols. For example, in November 2023, the Association of the British Pharmaceutical Industry (ABPI), a UK-based non-profit organization, reported that industry-sponsored clinical trials in the UK rose from 394 in 2021 to 411 in 2022, a 4.3% increase. This trend underscores how the growing number of clinical trials is propelling the gamma delta T cell cancer therapy market.

Companies in this market are advancing next-generation T cell engager (TCE) platforms to boost γδ T cell expansion, enhance targeting, and reduce off-tumor toxicity. γδ TCE platforms are engineered immunotherapies that redirect γδ T cells to recognize and kill cancer cells by linking them with tumor-associated antigens. In March 2025, IN8bio Inc., a US-based biotechnology company, launched the INB 600 platform. Its lead candidate, INB 619, targets CD19 and has demonstrated the ability to expand γδ T cells by up to 450 times in preclinical studies, resulting in significant B-cell depletion. This platform leverages the natural tumor-targeting ability of γδ T cells and enhances it with engineered engagers to improve specificity, reduce systemic side effects, and expand the range of treatable cancers.

In October 2023, Clade Therapeutics Inc., a US-based biotechnology company, acquired Gadeta B.V., a Netherlands-based firm specializing in γδ T cell therapies. This acquisition aims to integrate Gadeta’s gamma delta TCR technology to develop off-the-shelf, stem cell-derived T cell therapies with universal targeting capabilities for solid tumors, strengthening Clade Therapeutics’ pipeline and technological capabilities in the field.

Major players in the gamma delta t cell cancer therapy market are Novartis AG, Takeda Pharmaceutical Company Ltd., Legend Biotech Corporation, Immunocore Holdings plc, Immatics N.V., IN8bio Inc., American Gene Technologies International Inc., Adicet Bio Inc., LAVA Therapeutics N.V., Acepodia Inc., TC BioPharm (Holdings) plc, Century Therapeutics Inc., CytoMed Therapeutics Ltd., Appia Bio Inc., Expression Therapeutics Inc., ImCheck Therapeutics S.A.S., JY BioMed Inc., Kiromic BioPharma Inc., Luminary Therapeutics Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd.

North America was the largest region in the gamma delta T cell cancer therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gamma delta T cell cancer therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gamma delta T cell cancer therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Gamma delta T cell cancer therapy is an innovative immunotherapy approach that leverages the distinct properties of gamma delta T cells to identify and eliminate cancer cells without requiring antigen presentation via major histocompatibility complex (MHC) molecules. The main goal of this therapy is to utilize these cells’ inherent ability to recognize and destroy tumor cells, thereby boosting the body’s immune response against cancer.

The primary therapy types in gamma delta T cell cancer treatment include adoptive cell therapy, cytokine therapy, monoclonal antibodies, and combination therapies. Adoptive cell therapy involves transferring immune cells that have been activated or engineered outside the body to enhance their capacity to target and kill diseased cells. This approach is applicable to a wide range of cancers, including leukemia, lymphoma, solid tumors, and certain rare cancers, and can be used at various stages such as early, advanced, or relapsed/refractory stages. Its mechanisms of action include T cell activation, modulation of the tumor microenvironment, targeting tumor antigens, and enhancing immune checkpoint inhibition. These therapies serve diverse end users, including hospitals, specialized clinics, research institutions, and pharmaceutical companies.

The gamma delta T cell cancer therapy market research report is one of a series of new reports that provides gamma delta T cell cancer therapy market statistics, including gamma delta T cell cancer therapy industry global market size, regional shares, competitors with a gamma delta T cell cancer therapy market share, detailed gamma delta T cell cancer therapy market segments, market trends and opportunities, and any further data you may need to thrive in the gamma delta T cell cancer therapy industry. This gamma delta T cell cancer therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gamma delta T cell cancer therapy market consists of revenues earned by entities by providing services such as research and development of gamma delta T cell-based therapies, clinical trial support, immunotherapy development, patient-specific T cell engineering, and commercialization of targeted cancer treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The gamma delta T cell cancer therapy market also includes sales of gamma delta T cell therapy drugs, adoptive cell transfer kits, cell culture media and reagents, gene editing tools, and cryopreservation equipment. Values in this market are ‘factory gate’ values that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.